GlaxoSmithKline’s cervical cancer vaccine is definitely late to the party. While Merck sold $390 million of its Gardasil vaccine in the first quarter of this year, Glaxo sold a mere of $24 million worth of its Cervarix vaccine.
Just this morning, Cervarix got some bad news from France, where the health authority recommended against paying for [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment